Combination approaches are being investigated more and more in obesity treatment: the combined use of the gastric balloon and GLP-1 medications. This approach is still in the research stage, and the available preliminary data offer promising signals at the level of early indications; individual results may vary, and the final assessment must be made under physician supervision. In this article, we explain what we combine, why, and how, in clear, patient-oriented language.
Why Are We Considering Combination?
Both methods work on their own — but each has its limitations.
When GLP-1 receptor agonists are used alone:
- Strong hormonal appetite suppression
- An average of +5.63 kg regain when the medication is stopped (18 RCTs, 3,771 patients, EClinicalMedicine 2025, PMID: 41399474)
- The effect is medication-dependent — it requires continuous use
When the Allurion gastric balloon is used alone:
- An average of 14.9% TBWL (Ienca et al. 2020, PMID: 32279182)
- 95% weight maintenance after 1 year (Caballero et al. 2025, PMID: 40676353)
- Mechanical support limited to 16 weeks
The rationale for combination: Volumetric + hormonal suppression together; moreover, while behavioral habits settle onto a permanent foundation during the intensive 16-week balloon period, the GLP-1 RA can be safely tapered afterward.
Preliminary Clinical Data: 23% TBWL
The preliminary results announced by Allurion Technologies and Eli Lilly in February 2026:
N: 76 patients | TBWL: 23% | Protocol: Low-dose GLP-1/GIP receptor agonist + Allurion
This figure is above that of those using either method alone.
⚠️ Important note: These data are currently at the level of a press release. A peer-reviewed (refereed journal) publication is not yet available. It should be regarded as "preliminary results"; the full publication is pending.
How Does It Work?
The mechanisms of the two methods complement each other:
| Mechanism | GLP-1 RA | Allurion Balloon |
|---|---|---|
| Appetite reduction | ✓ Hormonal (brain + gut) | ✓ Volumetric (gastric fullness) |
| Slowing gastric emptying | ✓ | ✓ |
| Behavior change support | — | ✓ Program + App |
| Duration | Continuous use | 16 weeks |
| Lasting effect | Medication-dependent | Habit foundation |
In the combination, both pathways are active at the same time: hormonal suppression + mechanical fullness.
Why Is the Balloon Period Strategic?
During the period when the GLP-1 RA's effect is most pronounced — in the first 3–4 months — the balloon is also active. This overlap offers a favorable opportunity to "lock in" behavioral change during the window when weight loss is most intense.
Afterward:
- The balloon is passed (week 16)
- Behavioral habits have settled in
- The GLP-1 RA dose can be gradually reduced — the regain risk drops
This strategy may be an answer to the problem of "starting a GLP-1 without a plan to end treatment."
For Whom Can It Be Considered?
The combination is not yet a standard protocol. However, here is the candidate profile that may be evaluated in your consultation with your physician:
- You are using a GLP-1 RA and want additional support
- Your weight goal is hard to reach with a single method (>18% TBWL target)
- There is no medical contraindication for either GLP-1 or Allurion
- You want to reduce long-term medication use
Frequently Asked Questions
Is there a problem swallowing the gastric balloon while using GLP-1? Both methods slow gastric emptying. Nausea may increase in the first weeks. In a sequential protocol (balloon first, then GLP-1), this effect can be spread out. Your physician will determine the sequence appropriate for you.
Which GLP-1 is it combined with? The preliminary data cover the combination with a GLP-1/GIP receptor agonist. A systematic study with other GLP-1 RAs (GLP-1 receptor agonists, etc.) has not yet been published. We refrain from naming specific products — let your physician evaluate the right molecule for you.
Should it be used in combination or sequentially? Both approaches are being investigated. Concurrent (simultaneous) or successive (sequential) use is possible. There is not yet a finalized guideline.
When will a peer-reviewed publication appear? The full publication of the Allurion × Eli Lilly study is pending. This content will be updated when it appears.
Conclusion
The gastric balloon + GLP-1 combination is a synergistic approach that closes the weak points of both methods. Although the 23% TBWL preliminary data are promising, they are still at the "preliminary results" level. If you want to evaluate this protocol, talk to your specialist physician — and even if a standard protocol is still awaited, individual evaluation is already possible.
Individual results may vary. All treatment decisions should be made together with your specialist physician.
Continue reading:
- What Happens When You Stop GLP-1? →
- GLP-1 + Gastric Balloon in Detail →
- How Much Weight Can You Lose With a Gastric Balloon? →
- Clinical Evidence →
- Find a Specialist →
This content is for general informational purposes. The combination protocol requires individual medical evaluation.
Why Combination?
Both methods have strengths and weaknesses:
The strength of the Allurion balloon: Mechanical satiety enforces calorie restriction. It opens a 16-week structural window for behavior change. A one-time intervention.
The strength of GLP-1: Appetite suppression works centrally (at the brain level). It has a positive effect on glucose metabolism.
The potential of the combination: Because the two mechanisms work on different targets — hormonal and volumetric — a complementary mechanism of action appears likely. This hypothesis is consistent with the preliminary data whose peer-reviewed publication is still pending (preliminary); the full publication and a physician evaluation are required for a final assessment.
Current Clinical Evidence
Intragastric balloon + GLP-1 combination (PMID: 41212463): In a publication examining the combination of an intragastric balloon with a GLP-1 receptor agonist, preliminary findings were reported indicating that the two methods contribute through complementary mechanisms. Individual results may vary; the treatment decision should be made through a physician evaluation (PMID: 41212463).
Eli Lilly pilot data (n=76): The combination of Allurion + low-dose GLP-1/GIP receptor agonist reported an average of 23% TBWL in preliminary results (Data on File, Allurion 2026; see also PMID: 41212463). This preliminary numerical value is above the average ~15% (14.9%) TBWL level reported in clinical studies for Allurion monotherapy (PMID: 32279182); however, this comparison is based on preliminary data not verified by a peer-reviewed publication, individual results may vary, and the final assessment must be made under physician supervision.
Important note: The Eli Lilly data are preliminary in nature and were published in a press-release format. They have not undergone peer review. They should be interpreted with caution.
Ongoing clinical research: More comprehensive clinical studies examining the Allurion + GLP-1 combination are ongoing. This content will be updated when the peer-reviewed publications of these studies become available.
For Whom Can It Be Considered?
The combination protocol has not yet entered standard treatment guidelines. However, physicians may evaluate the following profiles:
- Patients who respond partially to GLP-1 therapy but find it inadequate
- Those who want to add GLP-1 during the post-balloon weight maintenance period
- Patients with a high BMI (≥38) targeting maximum effect who do not want surgery
Practical Questions
Who can administer the combination? Clinics experienced in both methods. An Allurion certification + GLP-1 prescribing authority is required.
How much does it cost? The costs of the two programs are added together. Although it may seem high, it can be evaluated relative to the surgical option.
Balloon first, then GLP-1? The most common protocol: balloon first, then transition-period support with a GLP-1 after 16 weeks. However, simultaneous initiation is also being investigated.
Is the combination FDA-approved? The two products are approved separately. The combination protocol falls under off-label use — it requires physician discretion and patient consent.
Managing Expectations
The combination is not a "magic formula." It does not give the same result for everyone. The basic rule does not change: behavior change is essential for lasting weight loss. The combination facilitates this change; it does not replace it.
Continue reading:
This content is for general informational purposes. The combination protocol requires individual medical evaluation.
Future Perspective
The "multi-modal" approach is gaining increasing acceptance in obesity treatment. The reality that no single method suits all patients has accelerated research supporting the combined use of more than one mechanism.
The Allurion + GLP-1 combination is one example of this trend. Peer-reviewed data from ongoing comprehensive clinical studies will determine whether this protocol enters standard guidelines.
For now: The preliminary data are promising, but the protocol has not yet been standardized. Consult your physician for the most up-to-date information.
Evaluate Within the Framework of a Program
Regardless of the choice of medication or combination, long-term success comes from being tied to a program. Allurion's 6-month integrated structure — capsule, digital tracking, nutritional support — provides this framework.
If you have used GLP-1 and need ongoing support, structural programs of this kind can play an important role during the transition period. Plan the most appropriate sequence together with your physician.
An Authorized Clinic in a City Near You
You can have the Allurion program performed at more than 60 authorized clinics across Türkiye. For clinics in major cities:
Clinical Sources
Related Articles
Weight Loss Injection Side Effects and Alternatives: A Balanced 2026 Guide
Weight loss injection (GLP-1) side effects, 2026 prices, and alternatives: real data, weight regain risk after stopping, and the swallowable gastric balloon option.
Gastric Balloon or GLP-1? Which Is More Effective in 2026?
Gastric balloon vs GLP-1 receptor agonists comparison: efficacy, sustainability, price, and side effects. A 2026 guide based on clinical data.
What Happens When You Stop Ozempic and GLP-1? Weight Regain Data
Do you regain weight after stopping GLP-1 drugs like Ozempic, Wegovy, and Mounjaro? The data, based on an 18-RCT meta-analysis and a BMJ 2026 review.
Related Pages
Which method is right for you?
Let our specialist physicians evaluate you free of charge.
Free Pre-Assessment →